For immediate release
2008 Survey Places Tengion in Top Ten for All Life Sciences Companies
Contact: Gary Sender
Chief Financial Officer
Tengion, Inc.
gary.sender@tengion.com
East Norriton, Pa., June 11, 2008 - Tengion, Inc., a clinical stage biotechnology company focused on the development of neo-organs and neo-tissues, has been recognized in The Scientist's 6th Annual Best Places to Work in Industry survey. Tengion was showcased as one of this year's Top Ten small companies (<1,000 employees), and ranked #7 among all companies based upon its success across 44 workplace criteria spread over 11 different categories. This year's global survey yielded responses from more than 200 large and small life sciences companies.
"This is a great acknowledgement of our efforts to create an innovative, collaborative and productive workplace for our novel product portfolio," said Steven Nichtberger, M.D., President and CEO of Tengion. "We are extremely proud of this honor and even more so of our employees' unwavering dedication to improving the lives of patients, which is why we all come to work every day."
According to The Scientist, this year's turnout for the annual survey was very strong and those companies that ranked highest were those that went the extra distance for employees and offered socially-progressive workplace policies. For the fifth consecutive year, employees at both large and small companies reported that the single most important factor is the feeling of personal satisfaction derived from the job and scientists working at the survey's leading companies felt they had the time and resources to pursue their scientific visions.
The Scientist's June issue is available now and features detailed survey results and profiles of the top 30 institutions overall - including Tengion.
About Tengion
Tengion, a clinical stage biotechnology company, focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using our Autologous Organ Regeneration Platform™. Tengion uses biocompatible materials and a patient's own (autologous) cells to create neo-organs or neo-tissues that are designed to catalyze the body's innate ability to regenerate. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information on the company and current clinical trials, visit Tengion online at: http://www.tengion.com.